國家衛生研究院 NHRI:Item 3990099045/12914
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 913610      Online Users : 1176
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12914


    Title: Association between gout, urate-lowering therapy, and risk of developing type 2 diabetes mellitus: A nationwide population-based retrospective cohort study
    Authors: Fang, YJ;Chung, YL;Lin, CL;Lim, YP
    Contributors: National Institute of Environmental Health Sciences;NHRI Graduate Student Program
    Abstract: Gout is the most prevalent inflammatory arthritis in adults. Although the link between gout and type 2 diabetes mellitus (T2DM) has been documented, our understanding of the association between urate-lowering therapy (ULT) among gout patients and T2DM development remains poor. We included 69,326 patients with new-onset gout in 2000-2011. Each case was matched randomly with 1 patient without gout during the study period, and 69,326 patients were recognized as the comparison cohort. A Cox proportional hazard regression model was used to analyze differences in the risk of T2DM development between patients with and without gout after considering related comorbidities. After adjusting for potential confounders, the case group had a higher risk of T2DM than the control cohort (adjusted hazard ratio oaHRTHORN = 1:30, 95%confidence interval oCITHORN = 1:24-1.38; P < 0:001). Gout patients without appropriate ULT had significantly higher risk of T2DM development than the control cohort (aHR = 1:39; 95%CI = 1:30-1.48; P < 0:001). Among gout patients, those receiving ULT excluding probenecid (aHR = 0:80; 95% CI = 0:64-1.00), all had significantly lower risk of T2DM than gout patients without ULT (all aHR < 0:90; all P < 0: 001). In this study, we found that gout increased the risk of T2DM; however, patients with any ULT exhibited a lower risk of T2DM than gout patients without any ULT (all aHR < 0:90, P < 0:001; excluding probenecid).
    Date: 2020-07
    Relation: Biomed Research International. 2020 Jul;2020:Article number 6358954.
    Link to: http://dx.doi.org/10.1155/2020/6358954
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000561369000001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85089320398
    Appears in Collections:[Others] Periodical Articles
    [Others] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    ISI000561369000001.pdf450KbAdobe PDF252View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback